Preclinical data further support the potential of dual-antigen and TGF-β-directed vaccines to reshape the tumor microenvironment and drive anti-tumor immunity NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) ...

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present two poster abstracts at the ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

Researchers from the International Institute of Molecular and Cell Biology in Warsaw (IIMCB) have described a new mechanism ...

As of Tuesday, April 15, iTeos Therapeutics, Inc.’s ITOS share price has surged by 7.59%, which has investors questioning if ...

To grow, cancer tumors must hijack the immune system for their needs. One of the main tricks that most tumors use is to manipulate a type of immune cell called a macrophage, causing it to protect the ...

Kiji Therapeutics engineered MSCs + IL-10 and CXCR4 offer tighter targeting and greater potency for challenging inflammatory diseases.

Combining a serum-free medium with a xeno-free serum replacement creates a reliable system for generating functional dendritic cells and macrophages. Myeloid cells such as dendritic cells and ...

One of the main tricks that most tumors use is to manipulate a type of immune cell called a macrophage, causing it to protect the tumor from the rest of the immune system, recruit blood vessels ...

Where S 0 is the area of the wound on day 0 after surgery and S t is the area of the wound on day t after surgery. The mycoplasma-negative mouse macrophage cell line RAW264.7 and mouse fibroblast cell ...